132539-06-1 (奥氮平,Olanzapine)

奥氮平;2-甲基-4-(4-甲基-1-哌嗪基)-10H-噻吩并[2,3-b][1,5]苯并二氮杂;奥兰扎平;奥兰氮平;2-甲基-4-(4-甲基-1-哌嗪基)-10H-噻吩并[2,3-B][1,5]苯并二氮杂卓;2-溴-5-甲氧基苯胺盐酸盐;Olanzapine 奥氮平;奥氮平 EP标准品;奥氮平 USP标准品;奥氮平 标准品;奥氮平-D4;奥氮平系统适用性 EP标准品;奥氮平杂质;硫酸核糖霉素;2-甲基-4-(4-甲基-1-哌嗪基)-10H-噻吩并[2,3-b][1,5]苯二氮䓬;奥氮平D8;奥氮平对照品;奥氮平(标准品);奥氮平 100MG;OLANZAPINE奥氮平原料;奥氮平, 一种5-HT2和D2受体高亲和性拮抗剂;奥氮平(对照品);奥氮平系统适用性;

2-Methyl-4-(4-methylpiperazin-1-yl)-10H-benzo[b]thieno[2,3-e][1,4]diazepine;2-METHYL-4-(4-METHYL-1-PIPERAZINYL)-10H-THIENO[2,3-B][1,5]BENZODIAZEPINE;lanzac;LY-170053;OLANZAPINE;OLANZAPINE FORM I;OLANZAPINE FORM II;ZYPREXA;OLANZAPINE INTERMEDIATE;Olanzapine solution;2-Methyl-4-(4-methyl-1-piperazinyl)- 10H-thieno[2,3-b][1,5]benzodiazepine LY-170053;Integrol;Larmac;LY170053;Oleanz;Oliza;Oltal;2-Methyl-4-(4-methyl-1-piperazinyl)- 10H-thieno[2,3-b][1,5]benzodiazepine;Olanzapine, >=99%;Zyprexa Zydis;Olansek;Zalasta;Zyprexa Intramuscular;Zyprexa Velotab;olanzapinum;Zypadhera;Zolafren;LY 170053;Olzapin;Oferta;10H-thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)-;N7U69;Olanzapine for system suitability;OLANZAPINE (USP-RS);AC-665;Z1521553472;BRD-K18895904-001-15-3;HMS2051H05;2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno(2,3-b)(1,5)benzodiazepine;C07322;NCGC00096077-18;KS-1090;CAS_132539-06-1;Olanzapine, 1mg/ml in Acetonitrile;DTXCID503388;NSC-801187;2-methyl-4-(4-methylpiperazin-1-yl)-5H-thieno[2,3-b][1,5]benzodiazepine;Olanzapine, >=98% (HPLC);OLANZAPINE [VANDF];SR-01000759343-6;BIDD:GT0332;HMS3884J21;OLANZAPINE [MI];Olanzapine Glenmark Europe;BDBM82479;ALKS-7921;A806453;Olanzapine for system suitability, European Pharmacopoeia (EP) Reference Standard;L005958;Midax;CAS-132539-06-1;OLANZAPINE [JAN];BIDD:PXR0138;OLANZAPINE [EMA EPAR];AB00639907-07;2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno-[2,3-b][1,5]benzodiazepine;HB1786;Olazax;DTXSID9023388;10H-Thieno(2,3-b)(1,5)benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)-;Olanzapin;AKOS005566122;Olanzapine (USAN:USP:INN:BAN);SBI-0206786.P001;OLANZAPINE COMPONENT OF LYBALVI;NSC-754829;Olanzapine (LY-170053);HY-14541;SPECTRUM1505024;OLANZAPINE (MART.);AB00639907_09;O0393;Olanzapine, Pharmaceutical Secondary Standard; Certified Reference Material;N05AH03;5-methyl-8-(4-methylpiperazin-1-yl)-4-thia-2,9-diazatricyclo[8.4.0.0,3,7]tetradeca-1(10),3(7),5,8,11,13-hexaene;Olanzapine (JAN/USP/INN);Olanzapine ( 1.0 mg/mL in Acetonitrile);HMS2233F24;NSC801187;AB00639907_08;LYBALVI COMPONENT OLANZAPINE;D00454;Olanzapine; 2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine; LY 170053; Lanzac; Zyprexa;BCP04917;5-methyl-8-(4-methylpiperazin-1-yl)-4-thia-2,9-diazatricyclo[8.4.0.0^{3,7}]tetradeca-1(10),3(7),5,8,11,13-hexaene;Tox21_111556;2-Methyl-4-(4-methylpiperazin-1-yl)-10H- thieno[2,3-b][1,5]benzodiazepin;BDBM35254;NCGC00096077-06;OLANZAPINE [USP-RS];EN300-119499;HMS3714J03;UNII-N7U69T4SZR;OLANZAPINE (USP MONOGRAPH);MLS001424057;Olanzapine, European Pharmacopoeia (EP) Reference Standard;SCHEMBL117695;Olanzapine-d8, 100 mug/mL in acetonitrile, ampule of 1 mL, certified reference material;Olanzapine Teva;SR-01000759343;olanzapina;OLANZAPINE [ORANGE BOOK];Olanzapine, United States Pharmacopeia (USP) Reference Standard;CS-1114;NCGC00096077-05;BRD-K18895904-001-16-1;US8802672, Olanzapine;NCGC00096077-01;MLS001165781;2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno(2,3- b)(1,5)benzodiazepine;SYMBYAX COMPONENT OLANZAPINE;2-methyl-4-(4-methylpiperazin-1-yl)-5H-thieno[3,2-c][1,5]benzodiazepine;NC00172;MFCD00866702;NCGC00096077-03;Olanzapine- Bio-X;AB00639907-06;(E)-2-methyl-4-(4-methylpiperazin-1-yl)-10H-benzo[b]thieno[2,3-e][1,4]diazepine;L000455;DB00334;s2493;Olanzapine (Zyprexa);Tox21_111556_1;2-methyl-4-(4-methylpiperazin-1-yl)-10H-thieno[2,3-b][1,5]benzodiazepine;Olanzapine?;2-methyl-4-(4-methyl-1-piperazinyl) -10h-thieno[2,3-b][1,5]benzodiazepine;CHEMBL715;NS00000036;OLANZAPINE (EP MONOGRAPH);Olanzapine Mylan;J-006186;PS15 - Olanzapine;OLANZAPINE [USAN];C17H20N4S;MLS000759457;SCHEMBL28763;NCGC00096077-20;CCG-100922;HMS3393H05;HMS3743A09;2-Methyl-10-(4-methyl-piperazin-1-yl)-4H-3-thia-4,9-diaza-benzo[f]azulene;OLANZAPINE COMPONENT OF SYMBYAX;HSDB 8155;SW220248-1;HMS2093I04;STK634338;132539-06-1;CHEBI:94534;GTPL47;HMS3657I15;Olanzapine 1.0 mg/ml in Acetonitrile;BCP9001021;Q201872;Olazax Disperzi;HMS3374L02;Olanzapine [USAN:USP:INN:BAN];ZYPREXAIntramuscular;HMS2089M04;STL388024;BO164166;GLXC-02527;N7U69T4SZR;2-methyl-4-(4-methyl-1-piperazinyl)-5H-thieno[3,2-c][1,5]benzodiazepine;OLANZAPINE [USP MONOGRAPH];OLANZAPINE [EP MONOGRAPH];Olanzapine Neopharma;MLS001195646;ALBB-027265;Olanzapine apotex;SMR000466345;NCGC00096077-04;NCGC00389791-02;BRD-K18895904-001-17-9;AKOS000282888;NSC_4585;OLANZAPINE [MART.];Olanzapine cipla;ZYPREXAZydis;OLANZAPINE [INN];NSC754829;Olanzapine Teva;Olanzapine Glenmark;SR-01000759343-4;2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine #;CHEBI:7735;OLANZAPINE [WHO-DD];

MFCD00866702

KVWDHTXUZHCGIO-UHFFFAOYSA-N

1S/C17H20N4S/c1-12-11-13-16(21-9-7-20(2)8-10-21)18-14-5-3-4-6-15(14)19-17(13)22-12/h3-6,11,19H,7-10H2,1-2H3

S1C(C([H])([H])[H])=C([H])C2=C1N([H])C1=C([H])C([H])=C([H])C([H])=C1N=C2N1C([H])([H])C([H])([H])N(C([H])([H])[H])C([H])([H])C1([H])[H]

200-835-2

一，用于控制精神分裂症、双极性躁狂症等疾病。  

二，为5HT2-D2拮抗剂。用于治疗精神分裂症。  

三，抗精神分裂症。 

 

4-氨基-2-甲基-10H-噻吩并[2，3-b][1，5]苯并二氮杂革盐酸盐和N-甲基哌嗪，在二甲亚砜和甲苯中，氮气保护下回流20h，得到奥氮平。

7655141

7655141